- Results of 5,993 Patient Study UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) Presented Today at European Respiratory Society Annual Congress - Not for U.S. Media Results of the UPLIFT trial, presented today at the European Respiratory Society (ERS) Annual Congress, demonstrated that tiotropium (SPIRIVA) administered to Chronic Obstructive Pulmonary Disease (COPD)patients, showed sustained improvements in lung function for up to 4 years (p<0.001), although it did not alter the rate of decline in lung function. The landmark study also reaffirmed the favourable safety profile of tiotropium.(1)... ...
Anytime
